29 November 2017 | News
The teams of Jubilant Biosys and Sanofi have worked closely on several first-in-class metabolic disease programs
Aiming to the discovery and development of small molecule inhibitors for multiple targets intended to achieve the medical needs in diabetes and obesity, union was done in 2016 as a part of a portfolio of programs.
From the beginning of this collaboration, the teams of Jubilant Biosys and Sanofi have worked closely on several first-in-class metabolic disease programs.
Jubilant Biosys confirmed receiving payment for the first milestone achievement for this collaboration.
Jubilant Biosys will continue to apply its effective integrated drug discovery platform to generate novel molecules that can demonstrate clinical proof of mechanism.
"Jubilant Biosys has invested in its metabolic disease platform to enable the discovery and development of small molecule therapeutics. We look forward to advancing these programs further through the discovery and development process to deliver important new therapeutics to treat diabetes," said Mr. Steven Hutchins, Jubilant Biosys, President, Drug Discovery Solutions.
Dr. Philip, Global Head of Diabetes Research & Chief Scientific Officer, Sanofi, Germany, said: "Sanofi works on continuously innovating to deliver value for people living with metabolic disorders. This productive collaboration with Jubilant Biosys further illustrates our commitment to discover and develop new therapies to support patients with diabetes or its complications."